{"name":"Longeveron","slug":"longeveron","ticker":"LGVN","exchange":"NASDAQ","domain":"longeveron.com","description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","hq":"Miami, FL","founded":0,"employees":"38","ceo":"Wa\\","sector":"Aging / Rare Disease / Regenerative Medicine","stockPrice":1.1,"stockChange":-0.06,"stockChangePercent":-5.17,"marketCap":"$32M","metrics":{"revenue":1200000,"revenueGrowth":-39.5,"grossMargin":67,"rdSpend":12041000,"netIncome":-22704000,"cash":4661000,"dividendYield":0,"peRatio":-0.7,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lomecel-B medicinal signaling cells","genericName":"Lomecel-B medicinal signaling cells","slug":"lomecel-b-medicinal-signaling-cells","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Lomecel-B medicinal signaling cells","genericName":"Lomecel-B medicinal signaling cells","slug":"lomecel-b-medicinal-signaling-cells","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Longeveron Announces FDA Clearance of IND for Lomecel-B in COVID-19","summary":"Longeveron announced that the FDA has cleared the Investigational New Drug (IND) application for Lomecel-B in COVID-19.","drugName":"Lomecel-B","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Longeveron Reports Third Quarter 2022 Financial Results","summary":"Longeveron reported its third-quarter 2022 financial results, with a net loss of $4.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"deal","headline":"Longeveron Announces Collaboration with University of Miami to Develop Lomecel-B for Heart Failure","summary":"Longeveron announced a collaboration with the University of Miami to develop Lomecel-B for heart failure.","drugName":"Lomecel-B","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE45cHRIbHVBWUR4ejdGcWE5VnZhMTR1Ul93bU1DOXV2LWxUWnFjMzZIVEw0bVg5U2s5dHhsOEFMbS1pSEZEVks3aXhLUjV2VDV2WTlIRF82YW51c08yNXgw?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"LGVN Stock Price, Quote & Chart | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill","headline":"LGVN Stock Price, Quote & Chart | LONGEVERON INC-A (NASDAQ:LGVN)","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE8zTFRwVTJpWGZrTGpHSnVKWnAyaHdRLWRLUW1yRVl4dWtmQ1Y5M01JenBzS3NDbkpRLWZJZWI5a1lRYTNGSEVPb1BzNGJlTGRxWmpfcEtSUmJHZk1JTTV5VXRDWEpORWRlT01DWXNR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Longeveron Inc (LGVN) - Stock Titan","headline":"If You Invested $1,000 in Longeveron Inc (LGVN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOTHVoUlBpSEtCcHFQREtESEVMeU5McWhhdjVXRHdWZmlpa09Hd3JEZ0h6d3R2OUpnajNhVTB3VkM5NGE5QnQ5OXZyQUZqNFk3QVNpMlVhS1dET05JZVRaUWxaNUNIb0h0N2loMlRDTjhHZFk5b1YwMmd3Uk01M2EweS1tMzQ0OVRudkxaanFZNWVhQkZzRGdmc3JuMjlsb0VhOUdrekJibTg1ZF9USGR0QlI4TXFadlFXcm5rdEtlRDJwclktX2xSQmJBUnU?oc=5","date":"2026-03-18","type":"earnings","source":"The Globe and Mail","summary":"Longeveron (LGVN) Q4 2025 Earnings Call Transcript - The Globe and Mail","headline":"Longeveron (LGVN) Q4 2025 Earnings Call Transcript","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNcjRBVTh4UVRSNmhkTFQ3UkdidU1sckt5U0w2WjVKVHFNRHlzQkZTbF9lX2Y4bTJOVkNReS1SUlU0ZnVWRG1CU193ZVFmOWJ0dUtuOFBXclhqSkxIZF9SU2MybUhoVTNwRGZfaXFuQlNMb3pleVNNUHJkbExVODB3RG9tOFJXRXV6UFJFeHVpeU1vV2JhOGY1bHgyOExoM0N1c1pXVFNOT1ZmcXdQRFhMV3QxMVlQOVVEZEJ2QUU4bVRJYUk?oc=5","date":"2026-03-13","type":"pipeline","source":"Stock Titan","summary":"Longeveron (LGVN) CEO discloses no beneficial share ownership - Stock Titan","headline":"Longeveron (LGVN) CEO discloses no beneficial share ownership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQWjZEZlcyc0N5MmpMM2I5bzU1MVQ4MUpOYmthaHZxNV9WSHlmQjd5MUwzYmxzVzhFcF90c3NrRnVQSGVIU05HTldyU1hibnluQ2FKSWpUdmdVYkhqeERKaXBtNWlkVjFMUGFJZVEyekhiamRLc0JJZHRpUGJUbDJGY3BjbzhrOG5DcEQ2eTdUMHhMS09PUzRFTGEzU05TQ2dTQkw5akhjazhzaThjdFl2RTJJZ0hjTHBo?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Biotech Longeveron to reveal 2025 results in March 17 call - Stock Titan","headline":"Biotech Longeveron to reveal 2025 results in March 17 call","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQMVY2WVVudjQ0M2UzVlVWRV9KSW9VdUZuTTVsZzBqejM5SXFGZExpam4zMHRUR2lTdy1COHJyekNqN0xNUnhDV3c4V2FLUHRsZkM0YWNPcXpsOUVnb29RZ0dLRFdvZXdLTmR6RGtHQS1mVnFzS01aNE96OG83bG1tYWtIdGxVV1NfdnhSWGtMVzRManNaU3ZKZEs3WUcwb2xjenhfYzFlUkV2RFBFdUtlbFkxZU9kRW8?oc=5","date":"2026-03-11","type":"trial","source":"Stock Titan","summary":"Biotech Longeveron secures $15M, cash runway past 2026 HLHS trial readout - Stock Titan","headline":"Biotech Longeveron secures $15M, cash runway past 2026 HLHS trial readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQbVJoS20tcUhMc2N1aDBYTVp0WnVDOUZ0ZUo4bjFTRlJoODFUY20zdDMxLXZ6LTZEM1ZIRk9ub2NucGhFVDJmOXFmTFFaVXA0dFdieXM5ajJiOUhmSnhnbTh5NERaOVVGTUV1UTFkakVQSkZrQVc5bUpldm4zRzhZdTVmd0VjV29mbXV2Nms4dmFycHJDeU5YX2t2RGhDblBJY3VPNjR4V20?oc=5","date":"2026-03-10","type":"trial","source":"Stock Titan","summary":"Longeveron secures $15M now, another $15M tied to HLHS trial milestones - Stock Titan","headline":"Longeveron secures $15M now, another $15M tied to HLHS trial milestones","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaVhDSHh5eklOcEM3Y1NSMERZMkJQd0JKWjZ6UWg3SWtVQjVJRS14MFhFYnNVZUozTGFVcC0zTXRiR1lrMVM4cVVaWGVBNnRYcGNqTmVWMU1sTEFMQVdmNDFxS0VpNGZ4Nmk2ZWZ4N2FZcGYtZTFEdHZsaU9kc0wwY0NIMUQzelRzcEN3VWw2cUhyd0UzaVZraEhNdWFWR3lORmhyTU1VQnRMTDFQdnRsOUdqRkpFczRBX2dYT2laei0?oc=5","date":"2026-01-26","type":"regulatory","source":"Stock Titan","summary":"Stem cell therapy for rare infant heart defect moves into key FDA talks - Stock Titan","headline":"Stem cell therapy for rare infant heart defect moves into key FDA talks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOUlpDRld6aEsxQUhubmRHZXdmejN5NzNMSW1wQzdRMWhpeWcwU1ZmVE1yeV9WVHlweTNxYWxraHdqQnR0VE5mdlR5X0JhTGY4QzljTkpTQWZiVjhIQVJKeXNlWUsxZUQyb29VZ2JKV2Y0clZkOWgyTDFvOElpOE9yMkJ0X01RNmw3NDBLRFJGU1FSRlQzQmMxRnNqU2J5VFJvSlU3YUdkTkI1TDhfNWxjNkEtWm04ck9C?oc=5","date":"2025-10-27","type":"trial","source":"Stock Titan","summary":"Longeveron (NASDAQ: LGVN) completes ELPIS II enrollment; HLHS trial top-line Q3 2026 - Stock Titan","headline":"Longeveron (NASDAQ: LGVN) completes ELPIS II enrollment; HLHS trial top-line Q3 2026","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioTime","Athersys","Mesoblast"],"therapeuticFocus":["Regenerative Medicine","Rare Diseases","Aging"],"financials":{"source":"sec_edgar","revenue":709000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":709000,"period":"2023-12-31"},{"value":1222000,"period":"2022-12-31"},{"value":1222000,"period":"2022-12-31"},{"value":1306000,"period":"2021-12-31"},{"value":1306000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12041000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-22704000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":10261000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.1,"previousClose":1.16,"fiftyTwoWeekHigh":1.83,"fiftyTwoWeekLow":0.47,"fiftyTwoWeekRange":"0.475 - 1.83","fiftyDayAverage":0.71,"twoHundredDayAverage":0.84,"beta":-0.19,"enterpriseValue":23153594,"forwardPE":-0.7,"priceToBook":4.45,"priceToSales":26.86,"enterpriseToRevenue":19.31,"enterpriseToEbitda":-1.05,"pegRatio":0,"ebitda":-22061000,"ebitdaMargin":0,"freeCashflow":-11171375,"operatingCashflow":-18645000,"totalDebt":824000,"debtToEquity":14.5,"currentRatio":1.33,"returnOnAssets":-81.3,"returnOnEquity":-164.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":5.48,"targetHighPrice":10.45,"targetLowPrice":2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.3,"institutionHeldPercent":6.1,"sharesOutstanding":27797133,"floatShares":19816913,"sharesShort":4553371,"shortRatio":0.32,"shortPercentOfFloat":15.6,"epsTrailing":-1.29,"epsForward":-1.53,"revenuePerShare":0.07,"bookValue":0.25,"officers":[{"age":62,"name":"Dr. Joshua Michael Hare FACC, M.D.","title":"Co-Founder, Chief Science Officer & Executive Chairman"},{"age":63,"name":"Ms. Lisa A. Locklear M.B.A.","title":"CFO, Executive VP & Treasurer"},{"age":57,"name":"Mr. Paul T. Lehr J.D.","title":"General Counsel & Secretary"},{"age":64,"name":"Mr. Stephen H. Willard Esq.","title":"Chief Executive Officer"},{"age":39,"name":"Mr. Devin  Blass","title":"CTO and Senior VP of Chemistry, Manufacturing & Controls"},{"age":55,"name":"Dr. Nataliya  Agafonova M.D.","title":"Chief Medical Officer"},{"age":54,"name":"Ms. Lisa  McClain-Moss","title":"Vice President of Manufacturing"},{"age":null,"name":"Mr. Brian G Rash Ph.D.","title":"Vice President of Research & Discovery"}],"industry":"Biotechnology","irWebsite":"","website":"https://longeveron.com","phone":"844 470 2550"}}